PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
2.620
+0.240 (10.08%)
At close: Oct 9, 2026, 4:00 PM EDT
2.500
-0.120 (-4.58%)
After-hours: Oct 9, 2026, 7:30 PM EDT
PepGen Employees
PepGen had 57 employees as of June 30, 2026. The number of employees decreased by 5 or -8.06% compared to the same quarter last year. That makes PepGen the 34,385th largest employer in the world and 4,577th in the United States.
Employees
57
Change
-5
Growth
-8.06%
Revenue / Employee
n/a
Profits / Employee
-$1,262,123
Market Cap
181.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 57 | -5 | -8.06% |
| Mar 31, 2026 | 59 | -20 | -25.32% |
| Dec 31, 2025 | 56 | -25 | -30.86% |
| Sep 30, 2025 | 57 | -19 | -25.00% |
| Jun 30, 2025 | 62 | -10 | -13.89% |
| Mar 31, 2025 | 79 | 14 | 21.54% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 13 | 20.63% |
| Jun 30, 2024 | 72 | 18 | 33.33% |
| Mar 31, 2024 | 65 | 16 | 32.65% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Sep 30, 2023 | 63 | 23 | 57.50% |
| Jun 30, 2023 | 54 | 18 | 50.00% |
| Mar 31, 2023 | 49 | 18 | 58.06% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Sep 30, 2022 | 40 | 17 | 73.91% |
| Jun 30, 2022 | 36 | 24 | 200.00% |
| Mar 31, 2022 | 31 | 19 | 158.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 144 |
| MediWound | 121 |
| Nkarta | 106 |
| Precision BioSciences | 67 |
| ALX Oncology Holdings | 48 |
| NovaBridge Biosciences | 30 |
| Cue Biopharma | 29 |
| Satellos Bioscience | 21 |
PEPG News
- 2 months ago - PepGen reports Q2 EPS (26c), consensus (29c) - TheFly
- 2 months ago - PepGen to advance PGN-EDODM1 into highest dose cohort - TheFly
- 2 months ago - PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - Business Wire
- 2 months ago - PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Business Wire
- 2 months ago - PepGen Quarterly report: Q2 2026 - Filings
- 2 months ago - PepGen Earnings release: Q2 2026 - Filings
- 2 months ago - PepGen Slides: Company presentation - Filings
- 3 months ago - Craig-Hallum bullish on PepGen, initiates with a Buy - TheFly